Anika Therapeutics Inc (ANIK) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Exhibit 99.1

Anika Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Monovisc^® Achieves FDA Approval

EPS Increases 42% to $0.44 in Quarter and 70% to $1.39 for Year

Cingal^TM Phase III Clinical Trial Enrollment Complete

Total Revenue for 2013 Grows to $75.1 Million

BEDFORD, Mass.--(BUSINESS WIRE)--February 26, 2014--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today reported financial results for the quarter and full year ended December 31, 2013.

Management Commentary

“Anika concluded a record year for revenue and earnings, driven by solid demand for our viscosupplementation products as well as productivity improvements in operations and manufacturing,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “Our top-line results for the fourth quarter were measured against a strong set of financial comparatives in the fourth quarter of 2012, which reflected a significant and temporary increase in product shipments in that year-earlier period.”

“Growth in 2013 continued to be fueled primarily by increased sales of our flagship product, Orthovisc^®, in both domestic and international markets,” Sherwood said. “We also made good progress this year in lowering our cost structure and improving the efficiency of our underlying operations. As a result, despite an increase in R&D spending due mainly to our multinational Phase III clinical study in support of our CE Mark application for Cingal^TM, Anika’s profitability for 2013 improved substantially year-over-year.”

“We are beginning 2014 in a strong position. Demand for our viscosupplementation products is growing, both in the U.S. and internationally. The FDA approval of Monovisc^® in the U.S. enhances our strength and flexibility in that market which should allow us to significantly increase market share. We are encouraged by the potential from our product pipeline, including Cingal^TM and Hyalofast^®. In addition, we are making good progress in building the internal capabilities that we need to expand beyond viscosupplementation and deliver on Anika’s potential in regenerative therapies. We believe that Anika is well-positioned for continued growth and profitability in the quarters ahead,” concluded Sherwood.